<DOC>
	<DOCNO>NCT02813577</DOCNO>
	<brief_summary>The post approval study enroll US female patient present claudication ischemic rest pain angiographically significant lesion superficial femoral popliteal artery . Subjects treat per Instructions For Use ( IFU ) Lutonix Catheter . Subjects Duplex Ultrasound ( DUS ) clinical follow-up two ( 2 ) year .</brief_summary>
	<brief_title>Lutonix Drug Coated Balloon Treatment Femoropopliteal Arteries United States Females ( CONFIRM )</brief_title>
	<detailed_description>The Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal angioplasty ( PTA ) Catheter ( Lutonix® Catheter ) approve Food Drug Administration ( P130024 ) percutaneous transluminal angioplasty , pre-dilatation , de novo restenotic lesion 150mm length native superficial femoral popliteal artery reference vessel diameter 4-6mm.The purpose trial ass safety effectiveness Lutonix Catheter treatment stenosis occlusion femoral popliteal artery United States ( US ) female population . This study enroll 160 female patient minimum 10 US center maximum 25 .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1 . Nonpregnant female ≥18 year age ; 2 . Rutherford Clinical Category 24 ; 3 . Patient willing provide inform consent , geographically stable , comply require follow visit test schedule ; Angiographic Criteria 4 . De novo nonstented restenotic lesion ( ) native superficial femoral popliteal artery ; 5 . Lesion length ≤150 mm ; Note : Lesion location start ≥1 cm common femoral bifurcation terminates distally ≤2 cm tibial plateau AND ≥1 cm origin tibialperoneal trunk : 6 . Lesion ≥70 % stenosis visual estimate ; 7 . Target reference vessel diameter 46mm 8 . Lesion ( ) locate least 3cm stent , target vessel previously stented ; Note : Successful inflow artery treatment define attainment residual diameter stenosis ≤30 % without death major vascular complication . 10 . At least one patent native outflow artery ankle , free significant ( ≥50 % ) stenosis confirm angiography previously revascularized ( treatment outflow disease NOT permit index procedure ) ; 11 . Successful antegrade wire cross predilatation target lesion ; Note : Successful predilatation define residual stenosis ≤30 % Lesion appropriate stenting due proximity knee joint . 12 . No prior vascular intervention within 2 week and/or plan 30 day protocol treatment except remote common femoral patch angioplasty separate least 2 cm lesion ( ) . 1 . Life expectancy &lt; 1 year 2 . Subject currently participate investigational drug device study previously enrol study ; Note : Enrollment another investigational drug device study follow period allow 3 . History stroke within 3 month ; 4 . History Myocardial Infarction ( MI ) , thrombolysis angina within 2 week index procedure ; 5 . Renal failure chronic kidney disease serum creatinine ≥2.5 mg/L within 30 day index procedure treat dialysis ; 6 . Sudden symptom onset , acute vessel occlusion , acute subacute thrombus target vessel ; 7 . Use adjunctive primary treatment modality ( i.e . laser , atherectomy , cryoplasty , cut balloon , etc . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Legs</keyword>
	<keyword>Drug Coated Angioplasty Balloon</keyword>
	<keyword>Experimental</keyword>
	<keyword>Standard Angioplasty Balloon</keyword>
</DOC>